Labs / CDMO: development & manufacturing

OmniParticles
Seoul, South Korea · omniparticles.com
GMP
On your own
Free. Their own form.
Through Midgard
Midgard sends your request to the lab and keeps the order's messages, papers and payments in one place. Free to ask. 1% platform fee if you keep the order on Midgard.
OmniParticles is a nanomedicine CDMO that develops nanoparticle drug substances and provides aseptic fill-finish for clinical-phase drug products. It operates in Seoul, Korea, with separate drug substance and drug product GMP facilities in the same building.
They take quote requests by email.
What they offer
Nanoparticle drug substance CDMO
End-to-end development and manufacturing for nanoparticle drug substances, from concept translation and formulation refinement through scale-up and GMP mass production with CMC support.
Aseptic sterile fill-finish
Aseptic fill-finish for preclinical and Phase I/II/III clinical supply, including batches of 2,000–5,000 vials under Grade A conditions in open RABS with a fully single-use product-contact train.
GMP and non-GMP drug substance manufacturing
Manufacturing of nanomedicine drug substance from preparation to purified bulk with GMP-compliant processes.
QC/QA analysis
QC/QA protocols for verifying nanomedicine integrity, safety, and performance against global regulatory standards.
Batch records and release documentation
Preparation of manufacturing reports, CoT, and CoA with full traceability to support regulatory filings.
CMC documentation and Module 3 CTD support
Preparation of essential CMC documentation and Module 3 scientific and technical writing for global regulatory submissions.
Regulatory consulting
Guidance on early-development regulatory strategy and global frameworks for IND and related clinical trial applications.
What they work on
- Modalities
- Small molecule, Antibody, Peptide, LNP / formulation
- Assays and studies
- DLS, TEM, zeta-potential, HPLC, SEC, ICP-MS, sterility testing
- Instruments and platforms
- DLS, TEM, zeta-potential, HPLC, SEC mode, triple detector, ICP-MS
- Scale and capacity
- batches of 2,000–5,000 vials, GMP drug substance manufacturing plant, purpose-built sterile drug product suite, two manufacturing suites
- Therapeutic areas
- acute diseases, chronic diseases, inflammatory diseases, ischemic stroke, intracerebral hemorrhage, sepsis, subarachnoid hemorrhage, traumatic brain injury
- Type
- CRDMO
- Sites
- Seoul, Korea
- Quality
- current EU GMP Annex 1 (sterile fill-finish suite and operations) · GMP (drug substance manufacturing and facility operations) · FDA IND approved (cerium oxide nanomedicine case highlight)
- Serves
- global
- Address
- Engineering 2021, 7 (9), 4446–4453 •Biomaterials 2020, 239, 119859 •ACS Nano
- Founded
- 2011
Similar labs. Esco Aster, CordenPharma, Adragos Pharma, ARSI Canada Inc
Found in a contract services directory. Listing built from omniparticles.com. Work here? Claim this listing.